[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Catholic University of Korea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,68,87,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054217","emotion-regulation-program-for-substance-use-disorders-100054217",false,"NCT07698821","Emotion Regulation Program for Substance Use Disorders","A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Emotion Regulation Program) for Substance Use Disorders","Inclusion Criteria:\n\n* Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent\n* Currently hospitalized (inpatient)\n* Able to communicate and complete questionnaires in Korean\n* Physically able to participate in program activities\n* Has completed detoxification treatment\n* Meets indication thresholds: DAST-10 score \\>= 2 and \\>= 2 DSM-5 criteria\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes communication\n* Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)\n* Acute psychotic symptoms or risk of self-harm or harm to others\n* At risk of disrupting group activities such that focus group participation is not feasible","ALL","19 Years","65 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study examines whether a newly developed eight-session psychosocial treatment program, called the Emotion Regulation Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.\n\nParticipants complete brief questionnaires and a short interview about their craving, motivation to change, difficulties in emotion regulation, self-compassion, depression, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.\n\nBecause this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.",[27],"Substance Use Disorder (SUD)",[29,30,31,32,33,34,35],"Psychosocial intervention","Craving","Group therapy","Acceptance and Commitment Therapy","Emotion regulation","Self-compassion","Motivation to change","NOT_YET_RECRUITING","2026-07-07",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-09",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"The Catholic University of Korea","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":48},"100053957","craving-management-program-for-substance-use-disorders-100053957","NCT07698808","Craving Management Program for Substance Use Disorders","A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Craving Management and Alternative Behavior Enhancement Program) for Substance Use Disorders","Inclusion Criteria:\n\n* Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent\n* Currently hospitalized (inpatient)\n* Able to communicate and complete questionnaires in Korean\n* Physically able to participate in program activities\n* Has completed detoxification treatment\n* Meets indication thresholds: DAST-10 score \\>= 2, craving reported as present on the VAS-C craving screening (i.e., \"yes\"), and \\>= 2 DSM-5 criteria\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes communication\n* Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)\n* Acute psychotic symptoms or risk of self-harm or harm to others\n* At risk of disrupting group activities such that focus group participation is not feasible\n* Individuals who are inmates or incarcerated at screening are not enrolled; participants who become incarcerated after enrollment are withdrawn",{"count":20,"type":21},[24],"This study examines whether a newly developed eight-session psychosocial treatment program, called the Craving Management and Alternative Behavior Enhancement Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, behavioral activation, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.\n\nParticipants complete brief questionnaires and a short interview about their craving, motivation to change, behavioral activation, positive and negative affect, mindfulness, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.\n\nBecause this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.",[27],[29,30,31,32,61,35,62],"Behavioral activation","Mindfulness",{"date":39,"type":40},{"date":65,"type":21},"2026-08",{"date":44,"type":21},{"name":46,"class":47},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":48},"100641308","first-step-program-for-substance-use-disorders-100641308","NCT07658963","First Step Program for Substance Use Disorders","A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (First Step Program) for Substance Use Disorders","Inclusion Criteria:\n\n* Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent\n* Currently hospitalized (inpatient)\n* Able to communicate and complete questionnaires in Korean\n* Physically able to participate in program activities\n* Has completed detoxification treatment\n* Meets indication thresholds: DAST-10 score \\>= 2, URICA-DO precontemplation or contemplation stage, and \\>= 2 DSM-5 criteria\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes communication\n* Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)\n* Acute psychotic symptoms or risk of self-harm or harm to others\n* At risk of disrupting group activities such that focus group participation is not feasible\n* Individuals who are inmates or incarcerated at screening are not enrolled; participants who become incarcerated after enrollment are withdrawn",{"count":20,"type":21},[24],"This study examines whether a newly developed four-session psychosocial treatment program, called the First Step Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, and group activities, and is delivered twice a week over about two weeks (four 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.\n\nParticipants complete brief questionnaires and a short interview about their motivation to change, craving, engagement in valued living, and social support before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.\n\nBecause this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.",[27],[29,30,31,32,35],"2026-06-15",{"date":82,"type":40},"2026-06-22",{"date":82,"type":21},{"date":85,"type":21},"2026-12-31",{"name":46,"class":47},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100544370","phase-4-effect-of-pregabalin-on-shoulder-pain-in-patients-with-central-sensitization-after-arthroscopic-rotator-cuff-repair-100544370","NCT06367998","Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair","The Effect of Pregabalin on Shoulder Pain of Patients With Myofascial Pain Syndrome and Central Sensitization Who Undergo Arthroscopic Rotator Cuff Repair","Inclusion Criteria:\n\n* Age over 19 to under 70\n* Underwent arthroscopic rotator cuff repair due to a tear of the rotator cuff.\n* Clinical diagnosis of myofascial pain syndrome\n* Central sensitization (Central Sensitization Inventory (CSI) score of 40 or above).\n\nExclusion Criteria:\n\n* Previous history of Pregabalin prescription\n* Hypersensitivity reactions or severe complications after taking Pregabalin.\n* Diagnosed with and are being treated for psychiatric disorders\n* Localized infection, sepsis, or previous neurological abnormalities\n* Uncontrolled hypertension (evidenced by a resting blood pressure of more than 100 mmHg)\n* Liver function abnormalities (aspartate aminotransferase or alanine aminotransferase \\>60 IU\u002Flitre).\n* major cardiovascular diseases or renal impairments",true,"20 Years","69 Years",{"count":98,"type":21},76,[100],"PHASE4","This study aims to investigate the effects of Pregabalin intake on shoulder pain management in patients with central sensitization undergoing arthroscopic rotator cuff repair. Although Pregabalin is known to be effective in controlling pain after shoulder arthroscopy, research on its efficacy in pain management for patients with central sensitization is scarce. Utilizing a list that identifies central sensitization, this study will explore whether Pregabalin can reduce postoperative pain in these patients and potentially improve joint mobility, emotional, and physical functioning. A prospective randomized study is planned, with inclusion criteria set for patients aged between 19 and 70 who have undergone arthroscopic rotator cuff repair.\n\nThe study will compare clinical outcomes up to one year postoperatively between two groups of 38 patients each. The case group will receive standard postoperative medications (NSAIDs) plus Pregabalin oral intake from the day before surgery to six weeks postoperatively, while the control group will receive only the standard postoperative medications without Pregabalin.",[103,104,105],"Rotator Cuff Tears","Central Sensitisation","Neuropathic Pain","2024-08-21",{"date":108,"type":40},"2024-08-23",{"date":110,"type":21},"2024-09-01",{"date":112,"type":21},"2026-05-01",{"name":46,"class":47},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":95,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100430802","outcome-of-neoadjuvant-chemotherapy-for-obstructive-colon-cancer-100430802","NCT04889820","Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer","Oncologic oUTcomes of Neoadjuvant Chemotherapy for obSTructive Colon cAncer After steNt Decompression (OUTSTAND Trial); Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* i. Age : 20 years old or more and lesser than 75 years old ii. Agreement of this study iii. Clinical stage II or III colon cancer with colonic obstruction which is confirmed by pathologic review and imaging study.\n\niv. Colon cancer located beween distal T colon and Rectosigmoid junction colon which is defined as a tumor above 15cm from anal verge.\n\nv. Colonocopic fiding: tumor involving whole circumference of the lumen, impossible to pass endoscope through the tumor vi. SEMS placement vii. no colonic injury and successful decompression of the colon with in 48 hours after SEMS placement.\n\nviii. ECOG performance 0-2 ix. ASA ≤ 3 x. Appropriate function of the vital organ (acceptable liver enzyme and BUN\u002FCr) xi. Appropriate function of hematopoietic system (platelet ≥100,000ul, neutrophil ≥2,000ul) xii. If the patient is female in fertile period, urine hCG test is negative and she has no plan of pregnancy with 6 months after the termiation of whole treatment.\n\nxiii. If the patient is male in fertile period, he agrees with contraception during treatment period and 6 months after the termination of whole treatment.\n\nExclusion Criteria:\n\n* i. any suspicious distant metastasis ii. any other primary malignant lesion iii. Clinical stage T1or T2 and N0 iv. the sign of perforation or severe ischemia requiring ememgency operation v. the complication related to SEMS placement (severe bleeding and perforation after SEMS placement) vi. ASA 4 or more vii. ECOG 3 or more viii. colonic obstruction by benign stricture ix. pregnant woman or woman who is breastfeeding x. the paitents who already enrolled into other study or are taking medicine related to any clinical trial xi. the patients who are taking sorivudine xii. the patients who are taking Tegafur\u002Fgimeracil\u002Foteracil xiii. the patietns who have a medical history of hypersensitivity reaction to 5-FU, oxaliplatin, leucovorin,or any medication including platinum.\n\nxiv. Inappropriate function of vital organ (impaired renal function, elevated liver enzyme, and so on ) xv. Inappropriate function of hematopoietic system (platelet \\\u003C100,000ul, neutrophil \\\u003C 2,000ul) xvi. Genetic problem such as galactose intolerance, Lapp lactase deficiency, or glucose-galatose malabsorption)","74 Years",{"count":123,"type":21},204,[24],"In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles. The primary end points is overall survival, also the short-term perioperative outcomes and long-term oncological outcomes will be compared between the control and experimental group. Random allocation will be carried out with the consent of patients and their guardians after successful SEMS placement, and 204 patients will be distributed between the two groups by 1:1.",[127],"Colon Cancer, Obstruction","2021-09-15",{"date":130,"type":40},"2021-09-22",{"date":132,"type":21},"2021-11-01",{"date":134,"type":21},"2027-10-31",{"name":46,"class":47},""]